Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor-α and Peroxisome Proliferator-Activated Receptor-γ Agonists

American Journal of Cardiology

Volumn 99, Issue 4 SUPPL., 2007, Pages 27-40

  Libby, Peter ^a   Plutzky, Jorge ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CELL NUCLEUS RECEPTOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; TRANSCRIPTION FACTOR;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETIC PATIENT; DRUG EFFECT; DYSLIPIDEMIA; FLUID RETENTION; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN TREATMENT; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN;

ANTILIPEMIC AGENTS; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERGLYCEMIA; PPAR ALPHA; PPAR GAMMA; RISK FACTORS;

EID: 33846898816     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.11.004     Document Type: Article

References (151)

1. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
2. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
3. Athyros V.G., Bouloukos V.I., Pehlivanidis A.N., Papageorgiou A.A., Dionysopoulou S.G., Symeonidis A.N., Petridis D.I., Kapousouzi M.I., Satsoglou E.A., Mikhailidis D.P., and MetS-Greece Collaborative Group. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab 7 (2005) 397-405
4. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., Smith Jr. S.C., Lenfant C., and Conference Participants. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
5. Reaven G. Insulin resistance, type 2 diabetes mellitus, and cardiovascular disease: the end of the beginning. Circulation 112 (2005) 3030-3032
6. Balkau B., and Charles M.A. Comment on the provisional report from the WHO consultation. Diabet Med 16 (1999) 442-443
7. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
8. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., Taskinen M.R., and Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
9. Malik S., Wong N.D., Franklin S.S., Kamath T.V., L'Italien G.J., Pio J.R., and Williams G.R. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110 (2004) 1245-1250
10. Ninomiya J.K., L'Italien G., Criqui M.H., Whyte J.L., Gamst A., and Chen R.S. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 109 (2004) 42-46
11. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28 (2005) 1769-1778
12. Kahn R., Buse J., Ferrannini E., Stern M., and American Diabetes Association and the European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
13. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 27 suppl (2004) S68-S71
14. Chait A., Brazg R.L., Tribble D.L., and Krauss R.M. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 94 (1993) 350-356
15. Castelli W.P., Garrison R.J., Wilson P.W., Abbott R.D., Kalousdian S., and Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 256 (1986) 2835-2838
16. Austin M.A., Hokanson J.E., and Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81 suppl (1998) 7B-12B
17. März W., Scharnagl H., Winkler K., Tiran A., Nauck M., Boehm B.O., and Winkelmann B.R. Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 110 (2004) 3068-3074
18. Goldberg R.B., Mellies M.J., Sacks F.M., Moye L.A., Howard B.V., Howard W.J., Davis B.R., Cole T.G., Pfeffer M.A., Braunwald E., and CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. Circulation 98 (1998) 2513-2519
19. Pyörälä K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., and Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 (1997) 614-620
20. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
21. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288 (2002) 2998-3007
22. Serruys P.W., de Feyter P., Macaya C., Kokott N., Puel J., Vrolix M., Branzi A., Bertolami M.C., Jackson G., Strauss B., Meier B., and Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287 (2002) 3215-3222
23. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., et al., PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
24. Collins R., Armitage J., Parish S., Sleigh P., Peto R., and Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
25. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., et al., ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
26. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackness M.I., Charlton-Menys V., Fuller J.H., and CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
27. Libby P., and Plutzky J. Diabetic macrovascular disease: the glucose paradox?. Circulation 106 (2002) 2760-2763
28. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
29. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1118
30. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., et al., PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
31. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., Menard J., Rahn K.H., Wedel H., Westerling S., and HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351 (1998) 1755-1762
32. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
33. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
34. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
35. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
36. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 83 (2006) 456S-460S
37. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338 (1998) 436-445
38. Amento E.P., Ehsani N., Palmer H., and Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 11 (1991) 1223-1230
39. Collins T., and Cybulsky M.I. NF-κB: pivotal mediator or innocent bystander in atherogenesis?. J Clin Invest 107 (2001) 255-264
40. Pradhan A.D., and Ridker P.M. Do atherosclerosis and type 2 diabetes share a common inflammatory basis?. Eur Heart J 23 (2002) 831-834
41. Baynes J.W., and Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48 (1999) 1-9
42. Pennathur S., and Heinecke J.W. Mechanisms of oxidative stress in diabetes: implications for the pathogenesis of vascular disease and antioxidant therapy. Front Biosci 9 (2004) 565-574
43. Yan S.F., Ramasamy R., Naka Y., and Schmidt A.M. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93 (2003) 1159-1169
44. Glass C. Going nuclear in metabolic and cardiovascular disease. J Clin Invest 116 (2006) 556-560
45. Shulman A.I., and Mangelsdorf D.J. Retinoid X receptor heterodimers in the metabolic syndrome. N Engl J Med 353 (2005) 604-615
46. Berger J., and Moller D.E. The mechanisms of action of PPARs. Annu Rev Med 53 (2002) 409-435
47. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Frick M.H., Elo O., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
48. Frick M.H., Syvanne M., Nieminen M.S., Kauma H., Majahalme S., Virtanen V., Kesaniemi Y.A., Pasternack A., Taskinen M.R., and Lopid Coronary Angiography Trial (LOCAT) Study Group. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 96 (1997) 2137-2143
49. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J., and Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
50. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
51. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357 (2001) 905-910
52. Heller F., and Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol 25 (1983) 57-63
53. Staels B., Vu-Dac N., Kosykh V.A., Saladin R., Fruchart J.C., Dallongeville J., and Auwerx J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase: a potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95 (1995) 705-712
54. Schoonjans K., Watanabe M., Suzuki H., Mahfoudi A., Krey G., Wahli W., Grimaldi P., Staels B., Yamamoto T., and Auwerx J. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem 270 (1995) 19269-19276
55. Martin G., Schoonjans K., Lefebvre A.M., Staels B., and Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators. J Biol Chem 272 (1997) 28210-28217
56. Malmendier C.L., and Delcroix C. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis 55 (1985) 161-169
57. Staels B., and Auwerx J. Regulation of apo A-I gene expression by fibrates. Atherosclerosis 137 suppl (1998) S19-S23
58. Koskinen P., Manttari M., Manninen V., Huttunen J.K., Heinonen O.P., and Frick M.H. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15 (1992) 820-825
59. Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J., Faas F.H., and Anderson J.W. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162 (2002) 2597-2604
60. Tenenbaum A., Motro M., Fisman E.Z., Tanne D., Boyko V., and Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 165 (2005) 1154-1160
61. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., et al., FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
62. Robins S.J., Collins D., Wittes J.T., Papademetriou V., Deedwania P.C., Schaefer E.J., McNamara J.R., Kashyap M.L., Hershman J.M., Wexler L.F., Rubins H.B., and VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285 (2001) 1585-1591
63. Tenkanen L., Manttari M., and Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation 92 (1995) 1779-1785
64. Chinetti G., Griglio S., Antonucci M., Torra I.P., Delerive P., Majd Z., Fruchart J.C., Chapman J., Najib J., and Staels B. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273 (1998) 25573-25580
65. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C., et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393 (1998) 790-793
66. Delerive P., Martin-Nizard F., Chinetti G., Trottein F., Fruchart J.C., Najib J., Duriez P., and Staels B. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85 (1999) 394-402
67. Marx N., Sukhova G.K., Collins T., Libby P., and Plutzky J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99 (1999) 3125-3131
68. Ziouzenkova O., Asatryan L., Sahady D., Orasanu G., Perrey S., Cutak B., Hassell T., Akiyama T.E., Berger J.P., Sevanian A., and Plutzky J. Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein. J Biol Chem 278 (2003) 39874-39881
69. Marx N., Mackman N., Schonbeck U., Yilmaz N., Hombach V., Libby P., and Plutzky J. PPARα activators inhibit tissue factor expression and activity in human monocytes. Circulation 103 (2001) 213-219
70. Neve B.P., Corseaux D., Chinetti G., Zawadzki C., Fruchart J.C., Duriez P., Staels B., and Jude B. PPARα agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 103 (2001) 207-212
71. Shu H., Wong B., Zhou G., Li Y., Berger J., Woods J.W., Wright S.D., and Cai T.Q. Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun 267 (2000) 345-349
72. Delerive P., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169 (2001) 453-459
73. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., and Staels B. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem 274 (1999) 32048-32054
74. Ogata T., Miyauchi T., Sakai S., Takanashi M., Irukayama-Tomobe Y., and Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-α activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-κ-B pathway. J Am Coll Cardiol 43 (2004) 1481-1488
75. Duez H., Chao Y.S., Hernandez M., Torpier G., Poulain P., Mundt S., Mallat Z., Teissier E., Burton C.A., Tedgui A., et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice. J Biol Chem 277 (2002) 48051-48057
76. Li A.C., Binder C.J., Gutierrez A., Brown K.K., Plotkin C.R., Pattison J.W., Valledor A.F., Davis R.A., Willson T.M., Witztum J.L., Palinski W., and Glass C.K. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J Clin Invest 114 (2004) 1564-1576
77. Hennuyer N., Tailleux A., Torpier G., Mezdour H., Fruchart J.C., Staels B., and Fievet C. PPARα, but not PPARγ, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 25 (2005) 1897-1902
78. Seki N., Bujo H., Jiang M., Shibasaki M., Takahashi K., Hashimoto N., and Saito Y. A potent activator of PPARα and γ reduces the vascular cell recruitment and inhibits the intimal thickening in hypercholesterolemic rabbits. Atherosclerosis 178 (2005) 1-7
79. Tordjman K., Bernal-Mizrachi C., Zemany L., Weng S., Feng C., Zhang F., Leone T.C., Coleman T., Kelly D.P., and Semenkovich C.F. PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest 107 (2001) 1025-1034
80. Berthou L., Duverger N., Emmanuel F., Langouet S., Auwerx J., Guillouzo A., Fruchart J.C., Rubin E., Denefle P., Staels B., and Branellec D. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 97 (1996) 2408-2416
81. Han C.Y., Chiba T., Campbell J.S., Fausto N., Chaisson M., Orasanu G., Plutzky J., and Chait A. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler Thromb Vasc Biol 26 (2006) 1806-1813
82. Despres J.P., Lemieux I., Pascot A., Almeras N., Dumont M., Nadeau A., Bergeron J., and Prud'homme D. Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. Arterioscler Thromb Vasc Biol 23 (2003) 702-703
83. Gervois P., Kleemann R., Pilon A., Percevault F., Koenig W., Staels B., and Kooistra T. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J Biol Chem 279 (2004) 16154-16160
84. Okopien B., Krysiak R., Kowalski J., Madej A., Belowski D., Zielinski M., Labuzek K., and Herman Z.S. The effect of statins and fibrates on interferon-γ and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 176 (2004) 327-335
85. Sebestjen M., Keber I., Zegura B., Simcic S., Bozic M., Fressart M.M., and Stegnar M. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb Haemost 92 (2004) 1129-1135
86. Okopien B., Krysiak R., Kowalski J., Madej A., Belowski D., Zielinski M., and Herman Z.S. Monocyte release of tumor necrosis factor-α and interleukin-1β in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J Cardiovasc Pharmacol 46 (2005) 377-386
87. Kowalski J., Okopien B., Madej A., Zielinski M., Belowski D., Kalina Z., and Herman Z.S. Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia. Eur J Clin Pharmacol 59 (2003) 189-193
88. Madej A., Okopien B., Kowalski J., Zielinski M., Wysocki J., Szygula B., Kalina Z., and Herman Z.S. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther 36 (1998) 345-349
89. Empen K., Frost R.J., Geiss H.C., Otto C., and Parhofer K.G. Differential effects of fenofibrate versus atorvastatin on the concentrations of E-selectin and vascular cellular adhesion molecule-1 in patients with type 2 diabetes mellitus and mixed hyperlipoproteinemia: a randomized cross-over trial. Cardiovasc Diabetol 2 (2003) 17
90. Marchesi S., Lupattelli G., Lombardini R., Roscini A.R., Siepi D., Vaudo G., Pirro M., Sinzinger H., Schillaci G., and Mannarino E. Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia. J Clin Pharm Ther 28 (2003) 419-424
91. Koh K.K., Ahn J.Y., Han S.H., Jin D.K., Kim H.S., Lee K.C., Shin E.K., and Sakuma I. Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. Atherosclerosis 174 (2004) 379-383
92. Koh K.K., Han S.H., Quon M.J., Yeal Ahn J., and Shin E.K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28 (2005) 1419-1424
93. Frost R.J., Otto C., Geiss H.C., Schwandt P., and Parhofer K.G. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 87 (2001) 44-48
94. Inoue I., Itoh F., Aoyagi S., Tazawa S., Kusama H., Akahane M., Mastunaga T., Hayashi K., Awata T., Komoda T., and Katayama S. Fibrate and statin synergistically increase the transcriptional activities of PPARα/RXRα and decrease the transactivation of NFκB. Biochem Biophys Res Commun 290 (2002) 131-139
95. National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel, Thompson P.D., Clarkson P.M., and Rosenson R.S. An assessment of statin safety by muscle experts. Am J Cardiol 97 suppl (2006) 69C-76C
96. Prueksaritanont T., Tang C., Qiu Y., Mu L., Subramanian R., and Lin J.H. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30 (2002) 1280-1287
97. Chang J.T., Staffa J.A., Parks M., and Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 13 (2004) 417-426
98. Ellen R.L., and McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 81 suppl (1998) 60B-65B
99. Farnier M., Dejager S., and French Fluvastatin Study Group. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. Am J Cardiol 85 (2000) 53-57
100. Athyros V.G., Papageorgiou A.A., Athyrou V.V., Demitriadis D.S., and Kontopoulos A.G. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 25 (2002) 1198-1202
101. Vega G.L., Ma P.T., Cater N.B., Filipchuk N., Meguro S., Garcia-Garcia A.B., and Grundy S.M. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 91 (2003) 956-960
102. Derosa G., Cicero A.E., Bertone G., Piccinni M.N., Ciccarelli L., and Roggeri D.E. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther 26 (2004) 1599-1607
103. Durrington P.N., Tuomilehto J., Hamann A., Kallend D., and Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 64 (2004) 137-151
104. Grundy S.M., Vega G.L., Yuan Z., Battisti W.P., Brady W.E., and Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 95 (2005) 462-468
105. Jones P.H., and Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95 (2005) 120-122
106. Davidson M.H. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 5 (2006) 145-156
107. Gerber P., Lubben G., Heusler S., and Dodo A. Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus. Curr Med Res Opin 19 (2003) 532-539
108. Sarafidis P.A., Lasaridis A.N., Nilsson P.M., Pagkalos E.M., Hitoglou-Makedou A.D., Pliakos C.I., Kazakos K.A., Yovos J.G., Zebekakis P.E., Tziolas I.M., and Tourkantonis A.N. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 22 (2004) 1769-1777
109. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., Tan M.H., Khan M.A., Perez A.T., Jacober S.J., and GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
110. Mukhtar R., and Reckless J.P. Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone. Diabet Med 22 suppl (2005) 6-10
111. Betteridge D.J., and Verges B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia 48 (2005) 2477-2481
112. Parhofer K.G., Otto C., Geiss H.C., Laubach E., and Goke B. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2-results of a pilot study. Exp Clin Endocrinol Diabetes 113 (2005) 49-52
113. Lawrence J.M., Reid J., Taylor G.J., Stirling C., and Reckless J.P. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 27 (2004) 41-46
114. Tan G.D., Fielding B.A., Currie J.M., Humphreys S.M., Desage M., Frayn K.N., Laville M., Vidal H., and Karpe F. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48 (2005) 83-95
115. van Wijk J.P., de Koning E.J., Castro Cabezas M., and Rabelink T.J. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care 28 (2005) 844-849
116. Sakamoto J., Kimura H., Moriyama S., Odaka H., Momose Y., Sugiyama Y., and Sawada H. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278 (2000) 704-711
117. Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., Witztum J.L., Auwerx J., Palinski W., and Glass C.K. Expression of the peroxisome proliferator-activated receptor gamma (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 95 (1998) 7614-7619
118. Law R.E., Goetze S., Xi X.P., Jackson S., Kawano Y., Demer L., Fishbein M.C., Meehan W.P., and Hsueh W.A. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 101 (2000) 1311-1318
119. Marx N., Sukhova G., Murphy C., Libby P., and Plutzky J. Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am J Pathol 153 (1998) 17-23
120. Marx N., Schonbeck U., Lazar M.A., Libby P., and Plutzky J. Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83 (1998) 1097-1103
121. Mehta J.L., Hu B., Chen J., and Li D. Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler Thromb Vasc Biol 23 (2003) 2203-2208
122. Pasceri V., Wu H.D., Willerson J.T., and Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 101 (2000) 235-238
123. de Dios S.T., Bruemmer D., Dilley R.J., Ivey M.E., Jennings G.L., Law R.E., and Little P.J. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 107 (2003) 2548-2550
124. Jiang C., Ting A.T., and Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
125. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
126. Marx N., Mach F., Sauty A., Leung J.H., Sarafi M.N., Ransohoff R.M., Libby P., Plutzky J., and Luster A.D. Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 164 (2000) 6503-6508
127. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., and Glass C.K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106 (2000) 523-531
128. Marx N., Duez H., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94 (2004) 1168-1178
129. Aljada A., Garg R., Ghanim H., Mohanty P., Hamouda W., Assian E., and Dandona P. Nuclear factor-κB suppressive and inhibitor-κB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?. J Clin Endocrinol Metab 86 (2001) 3250-3256
130. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
131. Marx N., Imhof A., Froehlich J., Siam L., Ittner J., Wierse G., Schmidt A., Maerz W., Hombach V., and Koenig W. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 107 (2003) 1954-1957
132. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., Al-Haddad W., Dhindsa S., and Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89 (2004) 2728-2735
133. Wang G., Wei J., Guan Y., Jin N., Mao J., and Wang X. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism 54 (2005) 590-597
134. Agarwal R. Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. Am J Physiol Renal Physiol 290 (2006) F600-F605
135. Marfella R., D'Amico M., Esposito K., Baldi A., Di Filippo C., Siniscalchi M., Sasso F.C., Portoghese M., Cirillo F., Cacciapuoti F., et al. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes 55 (2006) 622-632
136. Satoh N., Ogawa Y., Usui T., Tagami T., Kono S., Uesugi H., Sugiyama H., Sugawara A., Yamada K., Shimatsu A., Kuzuya H., and Nakao K. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26 (2003) 2493-2499
137. Chu C.S., Lee K.T., Lee M.Y., Su H.M., Voon W.C., Sheu S.H., and Lai W.T. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 97 (2006) 646-650
138. Langenfeld M.R., Forst T., Hohberg C., Kann P., Lubben G., Konrad T., Fullert S.D., Sachara C., and Pfutzner A. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111 (2005) 2525-2531
139. Sidhu J.S., Kaposzta Z., Markus H.S., and Kaski J.C. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24 (2004) 930-934
140. Choi D., Kim S.K., Choi S.H., Ko Y.G., Ahn C.W., Jang Y., Lim S.K., Lee H.C., and Cha B.S. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27 (2004) 2654-2660
141. Nishio K., Sakurai M., Kusuyama T., Shigemitsu M., Fukui T., Kawamura K., Itoh S., Konno N., and Katagiri T. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes [clinical investigation]. Diabetes Care 29 (2006) 101-106
142. Osman A., Otero J., Brizolara A., Waxman S., Stouffer G., Fitzgerald P., and Uretsky B.F. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J 147 (2004) e23
143. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., Le Winter M., Porte D., Semenkovich C.F., Smith S., Young L.H., Kahn R., and American Heart Association and the American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108 (2003) 2941-2948
144. Samaha F.F., Szapary P.O., Iqbal N., Williams M.M., Bloedon L.T., Kochar A., Wolfe M.L., and Rader D.J. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 26 (2006) 624-630
145. Home P.D., Pocock S.J., Beck-Nielsen H., Gomis R., Hanefeld M., Dargie H., Komajda M., Gubb J., Biswas N., and Jones N.P. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 48 (2005) 1726-1735
146. Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation (PERISCOPE). Current Controlled Trials. Available at: http://www.controlled-trials.com/mrct/trial/PERISCOPE/1059/122553.html. Accessed May 16, 2006.
147. Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J., Ochoa C., Kawakubo M., and Buchanan T.A. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55 (2006) 517-522
148. Kendall D.M., Rubin C.J., Mohideen P., Ledeine J.M., Belder R., Gross J., Norwood P., O'Mahony M., Sall K., Sloan G., et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 29 (2006) 1016-1023
149. Henke B.R. Peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes. J Med Chem 47 (2004) 4118-4127
150. Nissen S.E., Wolski K., and Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294 (2005) 2581-2586
151. ™ (tesaglitazar) [press release]. AstraZeneca Website. Available at: http://www.astrazeneca.com/pressrelease/5240.aspx. Accessed June 12, 2006.